BookingOverview
Doctor Simona Di Lascio has over 15 years’ experience as Medical Oncologist, having trained initially in Italy at “Gemelli” Hospital and Catholic University in Rome, an Hospital with 1530 beds, 96000 inpatients per year and 10 million outpatients services per year. She moved to Switzerland working at Oncology Institute of Southern Switzerland for about 10 years and completed a research fellowship in United States at Dana Farber Cancer Institute working in Breast Cancer Unit and at Broad Institute focusing in translational research in breast cancer. She completed research degree at Catholic University in Rome. She has worked at University Hospital in Siena (Italy) in Center of Immunotherapy and in University Hospital in Novara (Italy) in breast cancer center.
She has been involved as principal investigator and co-investigators in many clinical trials in Phase 1-2-3 and no-profit researches; is author and co-author of many scientific publications peer reviewed.
Has attended many international congresses and meeting and has been speaker in numerous national and international conferences on breast cancer. Her collaboration and research with international colleagues is ongoing.
She strongly believes that evidence based medicine, clinical research, international connections and continuous updating are the main tool to improve the quality of assistance and the care of our patients.
Specialties
Internal Oncologist
Services
- Breast cancer and others
September 2014- September 2017 : Catholic University del SacroCuore, Rome, Italy . PhD in oncology sciences
MARCH 2012 : Catholic University of Sacred Heart, Rome, Italy. Achievement of specialty in Medical Oncology ; Vote 50/50 with honours.
OCTOBER 2011 : Theoretical and practical course of CVC implant, type Picc
JULY 2007 : Catholic University of Sacred Heart, Rome, Italy. Qualification to the profession of physician. Level in national classification Vote 270/270
MARCH 2007: Catholic University of Sacred Heart, Rome, Italy. Degree in Medicine and Surgery (MD) Level in national classification 110/110, with honours.
July 2023- december 2023: Ospedale maggiore di Novara, Oncology department, Physician, involved in breast cancer treatment
January 2023- June 2023: University hospital of Siena, Immune-Oncology department and clinical trial unit, Physician, involved in clinical studies Phase 1-2-3.
October 2017- December 2022: Oncology institute of southern switzerland, Oncology department, Physician, head of clinic Oncology, main interest breast cancer
From September 2016 to august 2017 : Dana Farber Cancer Institute ( Boston), Research fellow in Breast Unit and at Broad Institute ( Boston)
From January 2016 To June 2016 : Oncology Institute of Southern Switzerland (IOSI), Oncology department, medical oncologist
From July 2014 to December 2015 : Ospedale La Carità Locarno, Internal Medicine department, Physician
FROM April 2012-TO June 2014 : Oncology Institute of Southern Switzerland (IOSI), Oncology department, research fellow in breast cancer
ESMO (European society for medical oncology/
ASCO (American society of clinical oncology
AIOM (Italian association of medical oncology
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.Tarantino P, Gupta H, DiLascio S, Tolaney SM, Lin NU.
Nat Commun. 2023 Nov 18;14(1):7496
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer.
Bancaro N, Calì B, Di Lascio S,.. Alimonti A.
Cancer Cell. 2023 Mar 13;41(3):602-619.e11
Arm Morbidity After Local Therapy for Young Breast Cancer Patients
Kuijer, A., Dominici, L.S., Rosenberg, S.M., ...Partridge, A.H., King, T.A.
Annals of Surgical Oncology, 2021, 28(11), pp. 6071–6082
Breast cancer in the oldest old (≥ 89 years): Tumor characteristics, treatment choices, clinical outcomes and literature review
Di Lascio, S., Tognazzo, E., Bigiotti, S., ...Pagani, O., Meani, F.
European Journal of Surgical Oncology, 2021, 47(4), pp. 796–803
Genomic Characterization of de novo Metastatic Breast Cancer
Garrido-Castro, A.C., Spurr, L.F., Hughes, M.E., Di Lascio ...Dillon, D.A., Lin, N.U.
Clinical Cancer Research, 2021, 27(4), pp. 1105–1118
Identifying ERBB2 activating mutations in HER2-negative breast cancer: Clinical impact of institute-wide genomic testing and enrollment in matched therapy trials
Exman, P., Garrido-Castro, A.C., Hughes, M.E., Di Lascio S....Wagle, N., Lin, N.U.
JCO Precision Oncology, 2019, 3
Vertebral augmentation for neoplastic lesions with posterior wall erosion and epidural mass
Cianfoni, A., Raz, E.,Di Lascio Mauri, S., ...Pesce, G., Bonaldi, G.
American Journal of Neuroradiology, 2015, 36(1), pp. 210–218
Foreign body mimicking lung cancer recurrence
Minerva, E.M., Patella, M.,Di Lascio., Inderbitzi, R., Cafarotti, S.
JCO Oncology Practice, 2020, 16(10), pp. 703–704
Paranasal sinus metastasis of breast cancer (BMJ Case Reports)
Di Lascio, S., Pittoni, P., Conti-Beltraminelli, M., ...Richetti, A., Pagani, O. BMJ case reports 2014
Unusual case of splenic sarcoidosis without morphological lesions detected by PET-CT in a patient with breast cancer: functional imaging between pitfalls and therapeutic guide
Paone, G., Di Lascio, S., Azzola, A., Mazzucchelli, L., Pagani, O.
ecancermedicalscience, 2017, 11, 766
Granular cell tumor of the breast: a multidisciplinary challenge
Meani, F., Di Lascio, S., Wandschneider, W., ...Generali, D., Pagani, O.
Critical Reviews in Oncology/Hematology, 2019, 144, 102828
Oligometastatic breast cancer: A shift from palliative to potentially curative treatment?
Di Lascio, S., Pagani, O.Breast Care 9(1), pp. 7-14 2014.
Hormonal therapies in young breast cancer patients: When, what and for how long?
Di Lascio, S., Christinat, A., Pagani, O.Journal of Thoracic Disease 5(SUPPL.1), pp. S36-S46 2013
Is it time to address survivorship in advanced breast cancer? A review article
Di Lascio, S., Pagani, O. The breast 2017,31,pp 167-172
New insights into endocrine therapy for young women with breast cancer
Di Lascio, S., Pagani, O.
Women's Health, 2015, 11(3), pp. 343–354
